Ligand Pharmaceuticals (LGND) Profit After Tax (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Profit After Tax of -$13.3 million for Q1 2026, down 129.8% sequentially from $44.8 million in Q4 2025, and up 68.56% YoY from -$7.9 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Profit After Tax (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Profit After Tax for 17 years, with the latest figure at -$13.3 million in Q1 2026.
- Quarterly Profit After Tax rose 68.56% year-over-year to -$13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (up 215.79% YoY) and the FY2025 annual result came in at $124.5 million, up 3186.63% from the prior year.
- Profit After Tax fell to -$13.3 million in Q1 2026 per LGND's latest filing, from $44.8 million in the prior quarter.
- Over five years, Profit After Tax peaked at $117.3 million in Q3 2025 and troughed at -$51.9 million in Q2 2024.
- A 5-year average of $7.4 million and a median of -$895000.0 in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax tumbled 2642.82% in 2023, then soared 1735.15% in 2025.
- Over 5 years, Profit After Tax stood at -$17.5 million in 2022, then soared by 204.02% to $18.2 million in 2023, then plunged by 270.93% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025, then tumbled by 129.8% to -$13.3 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 48.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.51 Mn |
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Sep 30, 2024 | -7.17 Mn |
| Jun 30, 2024 | -51.91 Mn |
| Mar 31, 2024 | 86.14 Mn |
| Dec 31, 2023 | 18.19 Mn |
| Sep 30, 2023 | -10.27 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 41.95 Mn |
| Dec 31, 2022 | -17.49 Mn |
| Sep 30, 2022 | 404,000.00 |
| Jun 30, 2022 | -895,000.00 |
| Mar 31, 2022 | -15.39 Mn |
| Dec 31, 2021 | -3.19 Mn |
| Sep 30, 2021 | 13.72 Mn |